For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and Attruby represents a genuine change. These innovative therapies protect the transthyretin protein, halting its damaging build-up and reducing the impact of the illness. Patients are now reporting positive outcomes